Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Clinical Update on the Current Management of Advanced Urothelial Bladder Cancer'

Featuring perspectives from Dr Petros Grivas, including the following topics: Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00) Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16) Perspective on recurrence mechanisms of NMIBC (22:21) Potential implications of circulating tumor DNA-based research in the management of bladder cancer (25:27) Importance of collaborative care for patients with bladder cancer (42:02) Frequency of HER2 expression and approach to HER2 testing for metastatic UBC (mUBC); activity of trastuzumab deruxtecan (T-DXd) in HER2-positive solid tumors (46:57) Monitoring and management of T-DXd-associated side effects (1:00:47) Efficacy and ongoing investigation of the HER2-targeted antibody-drug conjugate disitamab vedotin; other promising agents and strategies under investigation for mUBC (1:07:32) Results from the Phase III PROOF 302 trial of infigratinib versus placebo for patients with high-risk resected UBC with an FGFR3 genomic alteration (1:11:22) Potential association between intravesical bacillus Calmette-Guérin administration and lower risk of being diagnosed with Alzheimer's disease in patients with bladder cancer; feasibility of internet-based, patient-driven germline genetic testing (1:16:12) CME information and select publications